MOBILion System launches high-resolution Ion Mobility instrument

MOBILion is advancing separation science with the commercialisation of High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS) based on Structures for Lossless Ion Manipulation (SLIM).

This product addresses characterisation challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides resolution and reproducibility, faster, simpler method development, and greater instrument uptime. This new technology will help accelerate and simplify the workflows of challenging analyte classes including peptides, proteins, lipids and glycans, with analysis times five-60 times faster than conventional separation methods.

This technology, originally developed in the laboratory of Dr. Richard Smith at Pacific Northwest National Laboratory, is exclusively licenced for commercialisation purposed to MOBILion System.

“MOBIE can not only separate and identify molecules other instruments fail to detect, but it achieves superior performance with rapid analysis times, more efficient analyte-agnostic workflows, and more reproducible results, making it ideal for routine analysis,” said Dr. Melissa Sherman, CEO of MOBILion Systems.

Darlene Murphy, Vice President of Commercial Operations, MOBILion Systems added: “In 2017, we set our goal to launch at ASMS 2021 in Philadelphia, even with the pandemic delaying ASMS this year, we remained true to the plan and achieved our goals. In 2020, we completed a successful beta launch, where MOBIE was shown to provide fast, efficient, high resolution critical quality attribute (CQA) monitoring and was beneficial for scientists working with complex fast, efficient separations with and challenging analyte classes such as lipids and glycans. We hired our commercial team and are now ready to bring HRIM to our biopharma and research scientist customers more broadly.”

The full commercial product is available now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free